Bristol Myers Squibb Co. said Wednesday the European Commission has approved its drug nivolumab in combination with cabozantinib as a treatment for patients with advanced renal cell carcinoma.
The New York-based pharmaceutical company said the approval follows a Phase 3 trial result that showed the drug nivolumab, also known as Opdivo, in combination with Cabometyx--cabozantinib--significantly improved overall survival objective response rates compared to sunitinib--another cancer-treatment drug.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.